(Q27853359)

English

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

13 November 2016

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial (English)

1 reference

13 November 2016

phase II clinical trial

0 references

multicenter clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Louis Fehrenbacher

1

0 references

Alexander Spira

2

0 references

Marcus Ballinger

3

0 references

Marcin Kowanetz

4

0 references

Johan Vansteenkiste

5

0 references

Julien Mazieres

6

0 references

Keunchil Park

7

0 references

David Smith

8

0 references

Angel Artal-Cortes

9

0 references

Conrad Lewanski

10

0 references

Fadi Braiteh

11

0 references

Daniel Waterkamp

12

0 references

Pei He

13

0 references

Wei Zou

14

0 references

Daniel S Chen

15

0 references

Jing Yi

16

0 references

Alan Sandler

17

0 references

Achim Rittmeyer

18

0 references

language of work or name

0 references

publication date

30 April 2016

0 references

0 references

387

0 references

10030

0 references

1837-46

0 references

Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncology meets immunology: the cancer-immunity cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Control of Effector CD8 + T Cell Function by the Transcription Factor Eomesodermin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel transcription factor, T-bet, directs Th1 lineage commitment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900587-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(16)00587-0

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853359&oldid=1966144260"